Unicycive Historical Balance Sheet

UNCY Stock

USD 0.61 0.01 2.38%

Trend analysis of Unicycive Therapeutics balance sheet accounts such as Total Current Liabilities of 21.2 M, Net Tangible Assets of 19.9 M, Accounts Payable of 540.1 K or Total Current Assets of 16.2 M provides information on Unicycive Therapeutics' total assets, liabilities, and equity, which is the actual value of Unicycive Therapeutics to its prevalent stockholders. By breaking down trends over time using Unicycive Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Unicycive Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Unicycive Therapeutics is a good buy for the upcoming year.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

About Unicycive Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Unicycive Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Unicycive Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Unicycive Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Unicycive currently owns. An asset can also be divided into two categories, current and non-current.

Unicycive Therapeutics Balance Sheet Chart

At this time, Unicycive Therapeutics' Total Liabilities is fairly stable compared to the past year. Capital Stock is likely to rise to about 42.3 K in 2025, despite the fact that Retained Earnings are likely to grow to (55.2 M).

Total Current Liabilities Accounts Payable Total Current Assets Common Stock

Total Current Liabilities

Total Current Liabilities is an item on Unicycive Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Unicycive Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Unicycive Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Unicycive Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Most accounts from Unicycive Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Unicycive Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.At this time, Unicycive Therapeutics' Total Liabilities is fairly stable compared to the past year. Capital Stock is likely to rise to about 42.3 K in 2025, despite the fact that Retained Earnings are likely to grow to (55.2 M).

	2022	2023	2024	2025 (projected)
Total Current Assets	2.6M	13.4M	15.4M	16.2M
Accounts Payable	846K	821K	944.2K	540.1K

Total Current Assets Accounts Payable

Unicycive Therapeutics balance sheet Correlations

	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Total Current Assets	Common Stock	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Non Currrent Assets Other	Other Assets
Total Current Liabilities		0.79	-0.94	0.7	0.78	0.12	0.79	0.15	1.0	-0.31	-0.58	0.59	0.48	0.81	0.87	-0.2	0.94	0.94	1.0	-0.36	-0.34	0.99	-0.34	-0.17	-0.65	0.79
Net Tangible Assets	0.79		-0.91	0.94	0.9	-0.15	0.91	-0.12	0.8	0.18	-0.81	0.79	0.55	0.85	0.65	-0.53	0.95	0.95	0.8	0.12	-0.54	0.86	0.16	-0.34	-0.97	0.6
Retained Earnings	-0.94	-0.91		-0.87	-0.81	0.0	-0.82	-0.06	-0.94	0.19	0.65	-0.65	-0.5	-0.85	-0.84	0.34	-0.98	-0.98	-0.94	0.25	0.42	-0.96	0.22	0.22	0.8	-0.66
Accounts Payable	0.7	0.94	-0.87		0.81	-0.26	0.81	-0.03	0.71	0.16	-0.74	0.77	0.59	0.86	0.69	-0.46	0.88	0.87	0.71	0.11	-0.42	0.77	0.14	-0.22	-0.92	0.54
Total Current Assets	0.78	0.9	-0.81	0.81		-0.1	1.0	-0.02	0.79	0.35	-0.96	0.94	0.72	0.8	0.66	-0.39	0.88	0.89	0.79	0.29	-0.45	0.84	0.32	-0.26	-0.91	0.61
Common Stock	0.12	-0.15	0.0	-0.26	-0.1		-0.09	-0.35	0.14	-0.32	0.09	-0.07	-0.39	-0.17	0.33	-0.26	-0.04	-0.02	0.11	-0.37	-0.36	0.07	-0.32	-0.44	0.24	0.19
Total Assets	0.79	0.91	-0.82	0.81	1.0	-0.09		-0.01	0.8	0.33	-0.95	0.94	0.71	0.81	0.67	-0.39	0.89	0.9	0.8	0.27	-0.45	0.86	0.3	-0.27	-0.91	0.62
Short Long Term Debt Total	0.15	-0.12	-0.06	-0.03	-0.02	-0.35	-0.01		0.1	-0.27	0.15	-0.04	0.6	0.3	0.12	0.9	0.03	0.01	0.15	-0.16	0.87	0.08	-0.27	0.94	0.12	0.07
Other Current Liab	1.0	0.8	-0.94	0.71	0.79	0.14	0.8	0.1		-0.3	-0.6	0.6	0.45	0.79	0.87	-0.25	0.94	0.95	1.0	-0.36	-0.39	0.99	-0.33	-0.22	-0.65	0.79
Total Stockholder Equity	-0.31	0.18	0.19	0.16	0.35	-0.32	0.33	-0.27	-0.3		-0.57	0.54	0.35	0.0	-0.32	-0.31	-0.07	-0.06	-0.3	0.99	-0.19	-0.2	1.0	-0.16	-0.41	-0.24
Net Debt	-0.58	-0.81	0.65	-0.74	-0.96	0.09	-0.95	0.15	-0.6	-0.57		-0.98	-0.68	-0.64	-0.51	0.48	-0.73	-0.74	-0.59	-0.52	0.5	-0.67	-0.55	0.34	0.89	-0.41
Cash	0.59	0.79	-0.65	0.77	0.94	-0.07	0.94	-0.04	0.6	0.54	-0.98		0.75	0.71	0.6	-0.4	0.72	0.74	0.6	0.49	-0.41	0.66	0.52	-0.24	-0.87	0.47
Cash And Short Term Investments	0.48	0.55	-0.5	0.59	0.72	-0.39	0.71	0.6	0.45	0.35	-0.68	0.75		0.74	0.44	0.26	0.55	0.54	0.49	0.39	0.27	0.51	0.34	0.45	-0.63	0.36
Common Stock Total Equity	0.81	0.85	-0.85	0.86	0.8	-0.17	0.81	0.3	0.79	0.0	-0.64	0.71	0.74		0.77	-0.11	0.88	0.87	0.82	-0.02	-0.13	0.84	-0.02	0.07	-0.79	0.79
Common Stock Shares Outstanding	0.87	0.65	-0.84	0.69	0.66	0.33	0.67	0.12	0.87	-0.32	-0.51	0.6	0.44	0.77		-0.22	0.79	0.8	0.87	-0.36	-0.32	0.85	-0.34	-0.18	-0.53	0.77
Non Current Liabilities Total	-0.2	-0.53	0.34	-0.46	-0.39	-0.26	-0.39	0.9	-0.25	-0.31	0.48	-0.4	0.26	-0.11	-0.22		-0.38	-0.39	-0.2	-0.19	0.97	-0.29	-0.3	0.94	0.53	-0.17
Other Current Assets	0.94	0.95	-0.98	0.88	0.88	-0.04	0.89	0.03	0.94	-0.07	-0.73	0.72	0.55	0.88	0.79	-0.38		1.0	0.94	-0.13	-0.45	0.97	-0.1	-0.25	-0.86	0.73
Other Stockholder Equity	0.94	0.95	-0.98	0.87	0.89	-0.02	0.9	0.01	0.95	-0.06	-0.74	0.74	0.54	0.87	0.8	-0.39	1.0		0.95	-0.12	-0.47	0.98	-0.09	-0.27	-0.86	0.73
Total Liab	1.0	0.8	-0.94	0.71	0.79	0.11	0.8	0.15	1.0	-0.3	-0.59	0.6	0.49	0.82	0.87	-0.2	0.94	0.95		-0.35	-0.34	0.99	-0.33	-0.17	-0.66	0.79
Net Invested Capital	-0.36	0.12	0.25	0.11	0.29	-0.37	0.27	-0.16	-0.36	0.99	-0.52	0.49	0.39	-0.02	-0.36	-0.19	-0.13	-0.12	-0.35		-0.07	-0.26	0.99	-0.04	-0.35	-0.28
Short Long Term Debt	-0.34	-0.54	0.42	-0.42	-0.45	-0.36	-0.45	0.87	-0.39	-0.19	0.5	-0.41	0.27	-0.13	-0.32	0.97	-0.45	-0.47	-0.34	-0.07		-0.41	-0.18	0.97	0.5	-0.28
Capital Stock	0.99	0.86	-0.96	0.77	0.84	0.07	0.86	0.08	0.99	-0.2	-0.67	0.66	0.51	0.84	0.85	-0.29	0.97	0.98	0.99	-0.26	-0.41		-0.23	-0.23	-0.74	0.79
Net Working Capital	-0.34	0.16	0.22	0.14	0.32	-0.32	0.3	-0.27	-0.33	1.0	-0.55	0.52	0.34	-0.02	-0.34	-0.3	-0.1	-0.09	-0.33	0.99	-0.18	-0.23		-0.16	-0.38	-0.26
Short Term Debt	-0.17	-0.34	0.22	-0.22	-0.26	-0.44	-0.27	0.94	-0.22	-0.16	0.34	-0.24	0.45	0.07	-0.18	0.94	-0.25	-0.27	-0.17	-0.04	0.97	-0.23	-0.16		0.3	-0.17
Non Currrent Assets Other	-0.65	-0.97	0.8	-0.92	-0.91	0.24	-0.91	0.12	-0.65	-0.41	0.89	-0.87	-0.63	-0.79	-0.53	0.53	-0.86	-0.86	-0.66	-0.35	0.5	-0.74	-0.38	0.3		-0.45
Other Assets	0.79	0.6	-0.66	0.54	0.61	0.19	0.62	0.07	0.79	-0.24	-0.41	0.47	0.36	0.79	0.77	-0.17	0.73	0.73	0.79	-0.28	-0.28	0.79	-0.26	-0.17	-0.45

Click cells to compare fundamentals

Unicycive Therapeutics Account Relationship Matchups

Unicycive Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Current Liabilities	2.9M	2.1M	3.3M	17.5M	20.2M	21.2M
Retained Earnings	(5.9M)	(15.9M)	(34.0M)	(64.5M)	(58.1M)	(55.2M)
Accounts Payable	184K	713K	846K	821K	944.2K	540.1K
Total Current Assets	204K	18.4M	2.6M	13.4M	15.4M	16.2M
Common Stock	8K	9K	15K	35K	40.3K	21.3K
Total Assets	204K	18.7M	2.8M	14.2M	16.3M	17.1M
Short Long Term Debt Total	2.5M	306K	155K	811K	729.9K	679.4K
Other Current Liab	177K	1.1M	2.1M	16.4M	18.8M	19.8M
Total Stockholder Equity	(2.7M)	16.5M	(466K)	(3.8M)	(3.4M)	(3.3M)
Net Debt	2.5M	(16.3M)	(300K)	(8.9M)	(8.0M)	(7.6M)
Cash	0.0	16.6M	455K	9.7M	11.2M	5.9M
Non Current Assets Total	200.0K	333K	174K	792K	910.8K	956.3K
Liabilities And Stockholders Equity	204K	18.7M	2.8M	14.2M	16.3M	17.1M
Non Current Liabilities Total	2.7M	155K	1.0K	466K	419.4K	656.3K
Other Current Assets	204K	1.8M	2.2M	3.7M	4.3M	4.5M
Other Stockholder Equity	3.2M	32.4M	33.5M	60.7M	69.8M	73.3M
Total Liab	2.9M	2.3M	3.3M	18M	20.7M	21.7M
Net Invested Capital	(157K)	16.5M	(420K)	(3.8M)	(3.4M)	(3.2M)
Short Long Term Debt	2.5M	29K	46K	18K	16.2K	15.4K
Net Working Capital	(2.7M)	16.3M	(640K)	(4.1M)	(3.7M)	(3.5M)
Short Term Debt	2.5M	302K	310K	345K	310.5K	295.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Unicycive Historical Balance Sheet

About Unicycive Balance Sheet Analysis

Unicycive Therapeutics Balance Sheet Chart

Total Current Liabilities

Accounts Payable

Total Current Assets

Unicycive Therapeutics balance sheet Correlations

Unicycive Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Unicycive Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for Unicycive Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Liab	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Total Assets	+ 1.0	Total Current Assets
Total Liab	+ 1.0	Other Current Liab
Net Working Capital	+ 1.0	Total Stockholder Equity
Other Stockholder Equity	+ 1.0	Other Current Assets

Cash	- 0.98	Net Debt
Other Stockholder Equity	- 0.98	Retained Earnings
Other Current Assets	- 0.98	Retained Earnings
Non Currrent Assets Other	- 0.97	Net Tangible Assets
Net Debt	- 0.96	Total Current Assets
Capital Stock	- 0.96	Retained Earnings